Share Prices & Company Research

Stockbroking

4d Pharma Ord 0.25p

Current Price 94.50p Bid 92.50p Ask 96.50p Change 0.00%
Last Updated: 18/06/2019 03:38. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

4d pharma plc was founded in February 2014. It is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has completed a Phase I study in Irritable Bowel Syndrome and has completed dosing in a Phase I study in Paediatric Crohn's Disease. It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence one additional clinical study in 2018 and a further three in 2019.

Financial Highlights Year Ended 31/12/2018

Turnover
£0.00m
Operating Profit
£-28.37m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-2.57

Key Personnel

Duncan Joseph Peyton
Chief Executive Officer
Alexander James Stevenson
Chief Scientific Officer
David Robert Norwood
Non-Executive Chairman
Dr Edgardo Baracchini
Non-Executive Director
Prof Axel Gaston Glasmacher
Non-Executive Director
Thomas Engelen
Non-Executive Director

Stock Details

EPIC
DDDD
ISIN
GB00BJL5BR07
Shares in Issue
65,493,842
Market cap
£60.91m

Analyst Views (0)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
0.00p
Bid Price
92.50p
Ask Price
96.50p
Volume
0
Change Today
0.00p
% Change Today
0.00%
Open
0.00p
Previous Close
94.50p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
250.00p
52 Week Low
77.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

4d Pharma  Ord 0.25p Intra-day Chart

4d Pharma Ord 0.25p News

News in this section is provided by AJ Bell

Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 30 May 2019 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 23 May 2019 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 22 May 2019 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 22 May 2019 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 22 May 2019 | 09:00 4D pharma expects to deliver results from cancer study before year end 29 Apr 2019 | 09:51 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 14 Mar 2019 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 14 Mar 2019 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 13 Mar 2019 | 10:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 13 Mar 2019 | 10:00 4D pharma touts 2019 as 'important year' ahead of clinical readouts from lead programmes 08 Mar 2019 | 10:22 4d Pharma strikes alliance with University of Texas MD Anderson Cancer Center 07 Jan 2019 | 09:51 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 21 Dec 2018 | 09:35 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 19 Dec 2018 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 13 Dec 2018 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 13 Dec 2018 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 13 Dec 2018 | 09:00 Director Deals - 4d Pharma Plc Ord 0.25p (DDDD) 13 Dec 2018 | 09:00 4D pharma 'not aware' of reasons for share price drop 12 Dec 2018 | 09:59 4D Pharma reports modest uptick in losses on increased R&D costs 28 Sep 2018 | 09:56

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
4.9
5.2
Intangible Assets & Goodwill
14.5
14.7
Investments & Other Non-Current Assets
0.1
0.1
Total Non-Current Assets
19.5
19.9
Inventory
0.3
0.3
Trade & Receivables
1.3
3.2
Cash & Receivables
16.1
11.9
Other Current Assets & Assets Held for Resale
15.6
42.4
Total Assets
52.6
77.7

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
5.2
5.0
Long Term Liabilities
1.7
3.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
6.8
8.0

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
45.8
69.8

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
0.2
0.2
Minority Interests
0.0
0.0
Retained Earnings
-63.6
-39.9
Share Premium Account
108.3
108.3
Other Equity
0.9
1.2
Total Equity
45.8
69.8

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
-22.9
-17.2
Cashflow Before Financing
4.2
-16.8
Increase / Decrease in Cash
4.2
-16.8

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
0.0
0.0
Cost of Sales
0.0
0.0
Gross Profit
0.0
0.0
Operating Profit
-28.4
-24.4
Pre-Tax Profit
-28.4
-24.0
Profit / Loss for the Year
-23.7
-20.5
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.